ClinicalTrials.Veeva

Menu

The Drift-Reduction for Improved FFR Using Fiberoptic Technology (DRIFT) Study (OPSENS)

Columbia University logo

Columbia University

Status

Completed

Conditions

Left Anterior Descending Coronary Artery Stenosis

Treatments

Device: OpSens Medical OptoWire
Procedure: FFR

Study type

Interventional

Funder types

Other

Identifiers

NCT03848650
AAAR7661

Details and patient eligibility

About

The primary objective of this study is to assess the accuracy, efficacy, and durability of the OpSens Medical OptoWire Deux pressure wire in the assessment of angiographically intermediate proximal left anterior descending coronary artery (LAD) stenoses in clinical practice.

Full description

This study is designed as a prospective, observational in nature, multi-center, single-arm, clinical registry to estimate the ischemic burden of angiographically intermediate proximal LAD stenosis in clinical practice using the OpSens Medical OptoWire Deux FFR system. Subjects with stable angina or unstable angina who are found to have an intermediate proximal LAD stenosis on coronary angiography with anatomy amenable to PCI and underwent physiological lesion assessment with the OptoWire Deux pressure wire and OCT as part of their routine procedures using standard of care techniques will be enrolled. Patients meeting enrollment criteria will be offered the opportunity to enroll in this observational registry post-procedure. All patients enrolled in this study are expected to be evaluated and treated using a standard of care technique. This study will enroll a total of 60 patients at Columbia University Medical Center and St. Francis Hospital.

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female subjects, >18 years of age.
  • Patients with stable angina, unstable angina or non-ST segment elevation myocardial infarction (if the LAD lesion is the non-culprit lesion) and in whom an intermediate proximal LAD de novo stenosis (30-80%) with TIMI flow 3 has been identified on angiography. Note: Patients with multi-vessel disease can be enrolled.
  • Patients have had fractional flow reserve (FFR) and optical coherence tomography (OCT) of the LAD with the OpSens FFR system as part of their routine evaluation as standard of care procedure.
  • Provides written, informed consent and HIPAA consent to use the data in a clinical study.

Exclusion criteria

(General exclusion criteria)

  • Patients presented with NSTEMI with the LAD involved as the culprit lesion
  • Any ST-elevation myocardial infarction within the past 30 days.
  • Hemodynamic instability requiring vasopressor or mechanical circulatory support.
  • Prior heart transplant.
  • Known left ventricular ejection fraction ≤40%.
  • LAD supplying akinetic or severely hypokinetic territories if already known based on prior imaging.
  • Patient is enrolled in another clinical study that may impact the results of this study.
  • FFR not acquired per instructions for the OpSens Wire.
  • LAD Lesion not assessed with OCT.

(Angiographic exclusion criteria)

  • Thrombolysis in Myocardial Infarction (TIMI) grade 2 or lower at baseline angiography.
  • Target lesion involves left main (stenosis >50%).
  • Previous percutaneous coronary intervention (PCI) with stent in LAD or left main trunk.
  • Presence of chronic total occlusion in any vessel.
  • Presence of a side branch≥2.75 mm with ≥70% stenosis in the LAD.
  • Bifurcation lesion that resulted in the stent implantation of a side branch.

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

60 participants in 1 patient group

Opsens Medical OptoWire
Experimental group
Description:
Subjects who will have or recently had FFR using the Opsens Medical OptoWire Deux FFR system.
Treatment:
Procedure: FFR
Device: OpSens Medical OptoWire

Trial documents
1

Trial contacts and locations

2

Loading...

Central trial contact

Lauren Privitera, MS; Kate Dalton, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems